HORSHAM, Pa., Apr 12, 2004 /PRNewswire-FirstCall via COMTEX/ -- Centocor, Inc. today announced it has completed its acquisition of the former Wyeth (NYSE: WYE) St. Louis, MO, biopharmaceutical manufacturing facility. The transaction was announced on March 26, 2004.

Centocor will use this site to increase clinical material production for products currently in Centocor's pipeline. With the completion of this acquisition, Centocor now owns and operates four manufacturing facilities on two continents.

About Centocor

Centocor is a leading biomedicines company that creates, acquires and markets cost-effective therapies that yield long-term benefits for patients and the health care community. The company is dedicated to the research and development of treatments for a wide range of Immune-Mediated Inflammatory Disorders (I.M.I.D.), such as arthritis and inflammatory skin diseases, and for cancer. Centocor's products, developed primarily through monoclonal antibody technology, help physicians deliver innovative treatments to improve human health and restore patients' quality of life. Centocor is a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer of health care products.

Media Contact: Ron Schmid Centocor, Inc. Phone: (215) 325-6042 Mobile: (610) 659-3985

SOURCE Centocor, Inc.

Ron Schmid of Centocor, Inc., +1-215-325-6042, or cell, +1-610-659-3985

http://www.mcspr.com

Copyright ^© 2004 PR Newswire. All rights reserved.

News Provided by COMTEX

Close window | Back to top